These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 24693169)

  • 1. Conditions of tumor-associated antigens as a proper target for therapeutic antibodies against solid cancers.
    Kurosawa Y
    J Stem Cells Regen Med; 2011; 7(1):14-28. PubMed ID: 24693169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Identification of Tumor-associated Antigens via Isolation of Human Monoclonal Antibodies that may be Therapeutic.
    Kurosawa Y
    Immune Netw; 2009 Feb; 9(1):4-7. PubMed ID: 20107531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive screening for antigens overexpressed on carcinomas via isolation of human mAbs that may be therapeutic.
    Kurosawa G; Akahori Y; Morita M; Sumitomo M; Sato N; Muramatsu C; Eguchi K; Matsuda K; Takasaki A; Tanaka M; Iba Y; Hamada-Tsutsumi S; Ukai Y; Shiraishi M; Suzuki K; Kurosawa M; Fujiyama S; Takahashi N; Kato R; Mizoguchi Y; Shamoto M; Tsuda H; Sugiura M; Hattori Y; Miyakawa S; Shiroki R; Hoshinaga K; Hayashi N; Sugioka A; Kurosawa Y
    Proc Natl Acad Sci U S A; 2008 May; 105(20):7287-92. PubMed ID: 18474866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Classification of 27 Tumor-Associated Antigens by Histochemical Analysis of 36 Freshly Resected Lung Cancer Tissues.
    Kurosawa G; Sugiura M; Hattori Y; Tsuda H; Kurosawa Y
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity.
    Guo B; Ma ZW; Li H; Xu GL; Zheng P; Zhu B; Wu YZ; Zou Q
    Clin Immunol; 2008 Aug; 128(2):155-63. PubMed ID: 18502181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The therapeutic value of monoclonal antibodies directed against immunogenic tumor glycoproteins.
    Arlen M; Arlen P; Tsang A; Wang X; Gupta R
    J Cancer; 2010 Nov; 1():209-22. PubMed ID: 21060731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of two anti-CD5 monoclonal antibodies synergistically induces complement-dependent cytotoxicity of chronic lymphocytic leukaemia cells.
    Klitgaard JL; Koefoed K; Geisler C; Gadeberg OV; Frank DA; Petersen J; Jurlander J; Pedersen MW
    Br J Haematol; 2013 Oct; 163(2):182-93. PubMed ID: 23927424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving Immunotherapy Against B-Cell Malignancies Using γδ T-Cell-specific Stimulation and Therapeutic Monoclonal Antibodies.
    Hoeres T; Pretscher D; Holzmann E; Smetak M; Birkmann J; Triebel J; Bertsch T; Wilhelm M
    J Immunother; 2019; 42(9):331-344. PubMed ID: 31318724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analysis of Target Molecules towards Anti-cancer Therapeutic Antibodies].
    Masuko T
    Yakugaku Zasshi; 2021; 141(1):81-92. PubMed ID: 33390451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumour effects of single or combined monoclonal antibodies directed against membrane antigens expressed by human B cells leukaemia.
    Loisel S; André PA; Golay J; Buchegger F; Kadouche J; Cérutti M; Bologna L; Kosinski M; Viertl D; Delaloye AB; Berthou C; Mach JP; Boumsell L
    Mol Cancer; 2011 Apr; 10():42. PubMed ID: 21504579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.
    Vacchelli E; Pol J; Bloy N; Eggermont A; Cremer I; Fridman WH; Galon J; Marabelle A; Kohrt H; Zitvogel L; Kroemer G; Galluzzi L
    Oncoimmunology; 2015 Jan; 4(1):e985940. PubMed ID: 25949870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced cytotoxicity against colon carcinoma by combinations of noncompeting monoclonal antibodies to the 17-1A antigen.
    Fogler WE; Klinger MR; Abraham KG; Gottlinger HG; Riethmuller G; Daddona PE
    Cancer Res; 1988 Nov; 48(22):6303-8. PubMed ID: 2460221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-based therapy in colorectal cancer.
    Noguchi T; Ritter G; Nishikawa H
    Immunotherapy; 2013 May; 5(5):533-45. PubMed ID: 23638747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-β₂M monoclonal antibodies kill myeloma cells via cell- and complement-mediated cytotoxicity.
    Zhang M; Qian J; Lan Y; Lu Y; Li H; Hong B; Zheng Y; He J; Yang J; Yi Q
    Int J Cancer; 2014 Sep; 135(5):1132-41. PubMed ID: 24474467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant antibodies against ganglioside expressed on tumor cells.
    Hanai N; Nakamura K; Shitara K
    Cancer Chemother Pharmacol; 2000; 46 Suppl():S13-7. PubMed ID: 10950141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nectin-2 is a potential target for antibody therapy of breast and ovarian cancers.
    Oshima T; Sato S; Kato J; Ito Y; Watanabe T; Tsuji I; Hori A; Kurokawa T; Kokubo T
    Mol Cancer; 2013 Jun; 12():60. PubMed ID: 23758976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma.
    Decaup E; Rossi C; Gravelle P; Laurent C; Bordenave J; Tosolini M; Tourette A; Perrial E; Dumontet C; Poupot M; Klein C; Savina A; Fournié JJ; Bezombes C
    Front Immunol; 2019; 10():1943. PubMed ID: 31475004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibodies for the immunotherapy of solid tumours.
    Mauerer R; Gruber R
    Curr Pharm Biotechnol; 2012 Jun; 13(8):1385-98. PubMed ID: 22339220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes.
    Beum PV; Mack DA; Pawluczkowycz AW; Lindorfer MA; Taylor RP
    J Immunol; 2008 Dec; 181(11):8120-32. PubMed ID: 19018005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unusually efficient tumor cell lysis by human effectors of antibody-dependent cellular cytotoxicity mediated by monoclonal antibodies.
    Christiaansen JE; Sears DW
    Cancer Res; 1984 Sep; 44(9):3712-8. PubMed ID: 6744288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.